0 19

Cited 0 times in

Urgency to treat patients with chronic hepatitis C in Asia

Authors
 Jia‐Horng Kao  ;  Sang Hoon Ahn  ;  Rong‐Nan Chien  ;  Mong Cho  ;  Wan‐Long Chuang  ;  Sook‐Hyang Jeong  ;  Chen‐Hua Liu  ;  Seung‐Woon Paik 
Citation
 Journal of Gastroenterology and Hepatology, Vol.32(5) : 966-974, 2017 
Journal Title
 Journal of Gastroenterology and Hepatology 
ISSN
 0815-9319 
Issue Date
2017
MeSH
Antiviral Agents/therapeutic use* ; Asia/epidemiology ; Genotype ; Health Care Costs ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy* ; Hepatitis C, Chronic/economics ; Hepatitis C, Chronic/epidemiology ; Hepatitis C, Chronic/prevention & control ; Humans ; Interferons/therapeutic use* ; Prevalence
Keywords
Asia ; HCV clinical trials ; HCV treatment ; clinical ; hepatitis C
Abstract
Chronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South, and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for chronic hepatitis C vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians. However, low efficacy, poor safety profile, and subcutaneous administration limit the use of IFN-based therapies. Superior virologic outcomes have been observed with different classes of direct-acting antivirals (DAAs) alone or in combination, and several all-oral DAA regimens are available in Asia. These regimens have shown excellent efficacy and favorable tolerability in clinical trials, yet there is a need for further studies of DAAs in a real world context, particularly in Asia. Furthermore, IFN-free treatment may not be accessible for many patients in the region, and IFN-based regimens remain an option in some countries. There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost-effectiveness of IFN-free regimens. The evolution of potent treatments makes HCV eradication a possibility that should be available to all patients. However, access to these therapies in Asian countries has been slow, primarily because of economic barriers that continue to present a hurdle to optimal treatment.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/160962
DOI
10.1111/jgh.13709
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
안상훈(Ahn, Sang Hoon)
사서에게 알리기
  feedback
Full Text
https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13709
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse